301 related articles for article (PubMed ID: 17552141)
1. Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome.
Gravante G; Delogu D; Marianetti M; Trombetta M; Esposito G; Montone A
Eur Rev Med Pharmacol Sci; 2007; 11(2):119-27. PubMed ID: 17552141
[TBL] [Abstract][Full Text] [Related]
2. Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients.
Gravante G; Delogu D; Marianetti M; Esposito G; Montone A
Eur Rev Med Pharmacol Sci; 2007; 11(4):269-74. PubMed ID: 17876963
[TBL] [Abstract][Full Text] [Related]
3. A 12-year retrospective study of non-burn skin loss (burn-like syndromes) at a tertiary burns unit in a developing country.
Ugburo AO; Temiye EO; Ilombu CA
Burns; 2008 Aug; 34(5):637-43. PubMed ID: 18226456
[TBL] [Abstract][Full Text] [Related]
4. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
[TBL] [Abstract][Full Text] [Related]
5. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis.
Stella M; Clemente A; Bollero D; Risso D; Dalmasso P
Burns; 2007 Jun; 33(4):452-9. PubMed ID: 17475410
[TBL] [Abstract][Full Text] [Related]
6. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan.
Yamada H; Takamori K
Ther Apher Dial; 2008 Oct; 12(5):355-9. PubMed ID: 18937717
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Gueudry J; Roujeau JC; Binaghi M; Soubrane G; Muraine M
Arch Dermatol; 2009 Feb; 145(2):157-62. PubMed ID: 19221260
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
9. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
[TBL] [Abstract][Full Text] [Related]
10. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
11. Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Tougeron-Brousseau B; Delcampe A; Gueudry J; Vera L; Doan S; Hoang-Xuan T; Muraine M
Am J Ophthalmol; 2009 Dec; 148(6):852-9.e2. PubMed ID: 19837383
[TBL] [Abstract][Full Text] [Related]
12. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.
Schneck J; Fagot JP; Sekula P; Sassolas B; Roujeau JC; Mockenhaupt M
J Am Acad Dermatol; 2008 Jan; 58(1):33-40. PubMed ID: 17919775
[TBL] [Abstract][Full Text] [Related]
13. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids.
Shammas MC; Lai EC; Sarkar JS; Yang J; Starr CE; Sippel KC
Am J Ophthalmol; 2010 Feb; 149(2):203-213.e2. PubMed ID: 20005508
[TBL] [Abstract][Full Text] [Related]
14. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis.
Quinn AM; Brown K; Bonish BK; Curry J; Gordon KB; Sinacore J; Gamelli R; Nickoloff BJ
Arch Dermatol; 2005 Jun; 141(6):683-7. PubMed ID: 15967913
[TBL] [Abstract][Full Text] [Related]
15. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Yeung CK; Lam LK; Chan HH
Clin Exp Dermatol; 2005 Sep; 30(5):600-2. PubMed ID: 16045716
[No Abstract] [Full Text] [Related]
16. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].
Molgó M; Carreño N; Hoyos-Bachiloglu R; Andresen M; González S
Rev Med Chil; 2009 Mar; 137(3):383-9. PubMed ID: 19621180
[TBL] [Abstract][Full Text] [Related]
17. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ukponmwan CU; Njinaka I; Ehimiyen ET
Trop Doct; 2010 Jul; 40(3):167-8. PubMed ID: 20555046
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of histologic features of toxic epidermal necrolysis.
Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
[TBL] [Abstract][Full Text] [Related]
19. [Toxic epidermal necrolysis and Stevens-Johnson syndrome].
Roujeau JC
Rev Prat; 2007 Jun; 57(11):1165-70. PubMed ID: 17691257
[TBL] [Abstract][Full Text] [Related]
20. [Stevens-Johnson syndrome and toxic epidermal necrolysis; therapy policy in these life-threatening illnesses. Netherlands Work Group Toxic Epidermal Necrolysis].
van der Meer JB
Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1538-43. PubMed ID: 8765761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
